Trisol Medical has reported encouraging outcomes from its U.S. Early Feasibility Study of a transcatheter tricuspid valve replacement system.

• Clinical Observations: Initial data from 22 high-risk patients indicated notable reductions in tricuspid regurgitation and improvements in cardiac performance.
• Safety Profile: The study showed no device migration and a low rate of permanent pacemaker implantation within 30 days.

This summary is based on a press release issued by Trisol Medical.